A Phase I, Open-label Study to Evaluate the Relative Bioavailability of IDX184 and Food Effect in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 10 Feb 2015
At a glance
- Drugs IDX 184 (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 19 Nov 2012 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 16 Aug 2012 The US FDA has placed a partial clinical hold on IDX 184, according to a Idenix Pharmaceuticals media release.
- 27 Apr 2011 Dosing has been completed.